Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

4.0K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.0K
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

339
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
339
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

480
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
480
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

461
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
461
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

414
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
414
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

289
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
289

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Hospital Level Analysis of 30-Day Readmission Performance for Heart Failure Patients and Long-Term Survival: Findings from Get With The Guidelines-Heart Failure.

American heart journal·2018
Same author

Characteristics and Treatments of Patients Enrolled in the CHAMP-HF Registry Compared With Patients Enrolled in the PARADIGM-HF Trial.

Journal of the American Heart Association·2018
Same author

Home-Time After Discharge Among Patients Hospitalized With Heart Failure.

Journal of the American College of Cardiology·2018
Same author

Maximizing benefits and mitigating risks with mineralocorticoid receptor antagonist therapy.

European journal of heart failure·2018
Same author

Health Status Disparities by Sex, Race/Ethnicity, and Socioeconomic Status in Outpatients With Heart Failure.

JACC. Heart failure·2018
Same author

The Call for Precision Health Trials in Older Adults: One Size Does Not Fit All.

Journal of the American College of Cardiology·2018
Same journal

Stratified Medicine with Eplerenone for Myocardial Infarction or Injury and No obstructive Coronary Arteries: A Registry-Based Basket Trial.

American heart journal·2026
Same journal

Revised Lipid-Lowering Therapy Guidelines in a Nationally Representative Sample.

American heart journal·2026
Same journal

Cardiometabolic Health of Low- and Higher-Income Adults in the United States, 2009-2023.

American heart journal·2026
Same journal

Moving Beyond Technical Capability to Regulatory Integration for Digital Health Technology Devices-Brief Communication from the Cardiovascular Sciences Research Consortium.

American heart journal·2026
Same journal

THE SOCIETY OF CRITICAL CARE CARDIOLOGY - RATIONALE, BLUEPRINT, AND LESSONS LEARNED IN THE CREATION OF A NEW MULTIDISCIPLINARY PROFESSIONAL ORGANIZATION.

American heart journal·2026
Same journal

DOAC Score Among Patients Receiving Vitamin K Antagonists.

American heart journal·2026
See all related articles

Related Experiment Video

Updated: Jan 17, 2026

Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model
07:20

Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model

Published on: February 10, 2023

1.6K

Developing therapeutics for rare cardiovascular diseases.

Joseph B Lerman1, Dwight D Koeberl2, Shilpi Epstein3

  • 1Duke Clinical Research Institute, Durham, NC.

American Heart Journal
|September 14, 2025
PubMed
Summary
This summary is machine-generated.

Developing treatments for rare cardiovascular diseases faces challenges like diagnosis and small patient groups. Recent years show progress in creating therapies for these uncommon heart conditions.

More Related Videos

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
02:47

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

2.0K
A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft
08:30

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft

Published on: February 14, 2022

3.1K

Related Experiment Videos

Last Updated: Jan 17, 2026

Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model
07:20

Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model

Published on: February 10, 2023

1.6K
Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
02:47

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

2.0K
A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft
08:30

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft

Published on: February 14, 2022

3.1K

Area of Science:

  • Cardiology
  • Rare Diseases
  • Drug Development

Background:

  • Rare cardiovascular diseases collectively impact millions globally, causing significant morbidity and mortality.
  • Most rare cardiovascular diseases currently lack approved therapeutic interventions.
  • These conditions present unique challenges in research and treatment development.

Purpose of the Study:

  • To provide an overview of the challenges in developing therapies for rare cardiovascular diseases.
  • To highlight potential strategies for advancing the field of rare cardiovascular disease treatment.
  • To review the progress made in the last decade.

Main Methods:

  • Literature review of challenges and strategies in rare cardiovascular disease therapy development.
  • Analysis of barriers including diagnosis, cohort size, endpoints, ethics, and cost.
  • Examination of recent successful therapy developments.

Main Results:

  • Key challenges identified: diagnostic delays, small patient cohorts, endpoint selection, ethical/regulatory issues, and high therapy costs.
  • Despite challenges, a notable increase in successful rare cardiovascular disease therapy development occurred in the past decade.
  • Strategies to overcome these hurdles are crucial for future progress.

Conclusions:

  • Therapy development for rare cardiovascular diseases is complex but achievable.
  • Overcoming diagnostic, logistical, and financial barriers is essential.
  • Continued innovation and strategic approaches are advancing treatment options for rare heart conditions.